Joseph Desrosiers
Medical · Providence, RINPI 1447753728
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 128 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 19 manufacturers reported payments, led by AbbVie at 38.9% of the total. Reporting peaked in 2021 at $831 and has fallen 95.1% since, to $40 in 2025.
Across 128 payments — averaging $17.49 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$871
- AstraZeneca$353
- Nestle Healthcare Nutrition Inc.$290
- GSK$111
- Esperion Therapeutics, Inc.$109
- Lilly USA, LLC$81
- plus $425 from 13 others
What the payments were for
- Food & beverage$2,239100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 50 | $871 |
| AstraZeneca | 21 | $353 |
| Nestle Healthcare Nutrition Inc. | 17 | $290 |
| GSK | 6 | $111 |
| Esperion Therapeutics, Inc. | 7 | $109 |
| Lilly USA, LLC | 4 | $81 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 4 | $71 |
| Amgen | 4 | $64 |
| Abbott | 3 | $56 |
| Astellas Pharma US Inc | 2 | $44 |
| Daiichi Sankyo Inc. | 2 | $33 |
| Biohaven Pharmaceutical Holding Company Ltd. | 1 | $28 |
| E.r. Squibb & Sons, L.L.C. | 1 | $22 |
| Ironwood Pharmaceuticals, Inc | 1 | $21 |
| Idorsia Pharmaceuticals US Inc | 1 | $20 |
| Organon | 1 | $17 |
| Exact Sciences | 1 | $17 |
| Mylan Specialty L.p. | 1 | $16 |
| Boehringer Ingelheim | 1 | $16 |
How this compares
$2,239 in reported general payments places this provider in the 75th percentile of 77 medical providers in Rhode Island.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Buprenorphine-NaloxoneBuprenorphine Hcl/Naloxone Hcl | 16 | $1,502 |
| Clobetasol EmollientClobetasol Propionate/Emoll | 17 | $1,237 |
| Atorvastatin Calcium | 61 | $682 |
| Levothyroxine Sodium | 37 | $651 |
| Aripiprazole | 15 | $548 |
| Quetiapine Fumarate | 16 | $455 |
| Omeprazole | 30 | $435 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 17 | $428 |
| Montelukast Sodium | 17 | $338 |
| Rosuvastatin Calcium | 22 | $328 |
| Losartan Potassium | 25 | $319 |
| Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen | 13 | $300 |
| Gabapentin | 14 | $296 |
| Lisinopril | 33 | $258 |
| Amlodipine Besylate | 38 | $247 |
Paid to pharmacies, not to this prescriber.
Other medical in Providence
- Amanda MattesonProvidence$8K
- Jason XynellisProvidence$7K
- Ian KrousonProvidence$5K
- Ernest SilvaProvidence$3K
- Kailey WellsProvidence$2K
- Daniel PiascikProvidence$2K
- Sonia PeckProvidence$2K
- Phathsady LouangxayProvidence$1K
- Shauna SnitkoProvidence$835
- Kenneth FurcoloProvidence$511
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.